Table 1.

Antiangiogenic therapy plus immune checkpoint blockade clinical trials.

Trial Name/NCT Number	Phase	Drugs	Eligible Patients	Dose/Schedule	Findings of Primary Endpoint(s)	Findings of Secondary Endpoint(s)	Notable common grade AEs (≥10%)
Completed antiangiogenic therapy + ICB trials
IMagyn050  NCT03038100  Moore KN, et al. Annals of Oncology (2020). Abstract.	Randomized, double-blind phase III	SOC plus bevacizumab (bev) plus atezolizumab (atezo)	Newly diagnosed, advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (n = 1301)	Platinum-based chemotherapy (carboplatin plus paclitaxel) for 6 cycles plus bev 15 mg/kg IV for 2–6 cycles plus atezo 1200 mg IV q3w for 6 cycles or placebo Maintenance bev 15 mg/kg IV q3w plus atezo 1200 mg IV q3w for 16 cycles or placebo	Median PFS in intent-to-treat population: 18.4 mo placebo, vs. 19.5 mo atezo (HR = 0.92, 0.79–1.07) Median PFS in PD-L1± population: 18.5 mo placebo, vs. 20.8 mo atezo (HR = 0.80, 0.65–0.99)	ORR, duration of response, safety & tolerability	No reported or published data; further analysis pending
NCT02873962  Liu JF, et al. JAMA Oncol (2019).	Open-label, single arm phase II	Bevacizumab (bev) plus nivolumab (nivo)	Platinum-sensitive (n = 20) or platinum-resistant (n = 18) recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (n = 38)	Bev 10 mg/kg IV q2w plus nivo 240 mg IV q2w	ORR: 28.9% (15.4–45.9)	ORR by platinum sensitivity: 40.0% (19.1–64.0) platinum-sensitive vs. 16.7% (3.6–41.4) platinum-resistant Median PFS: 9.4 mo (6.7-NA); 12.1 (8.4-NA) platinum-sensitive vs. 7.7 mo (4.7-NA) platinum-resistant	No grade 3/4 AEs ≥ 10% were observed Hypertension was observed in 26.3% of all patients (5.3% experienced grade 3/4)
Ongoing/incomplete antiangiogenic therapy + ICB trials
ATALANTE  NCT02891824  Kurtz JE, et al. Journal of Clinical Oncology (2018).	Randomized, double-blind, phase III	SOC plus bevacizumab (bev) plus atezolizumab (atezo)	Platinum-sensitive, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (n = 614)	Platinum-based chemotherapy (carboplatin plus gemcitabine/paclitaxel/PLD) plus bev plus placebo (arm A) vs. atezo (arm B) for 6 cycles Maintenance with placebo (arm A) vs. atezo (arm B) until progression	PFS	TSST, OS, safety & tolerability	No reported or published data
EORTC-1508  NCT02659384	Randomized, triple-blind phase II	Bevacizumab (bev), atezolizumab (atezo), plus acetylsalicylic acid (ASA)	Platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer	Bev alone (arm 1) vs. bev plus atezo plus placebo (arm 2) vs. bev plus atezo plus ASA (arm 3)	PFS		No reported or published data
NRG-GY009  NCT02839707	Randomized, open-label phase II/III	PLD plus bevacizumab (bev) plus atezolizumab (atezo)	Platinum-resistant recurrent high-grade ovarian, fallopian tube, or primary peritoneal cancer	PLD plus atezo (arm 1) vs. PLD + atezo + bev (arm 2) vs. PLD + bev (arm 3)	PFS (phases II & III) OS (phase UI)	ORR, PD-Ll expression, safety & tolerability	No reported or published data

^*All reported ranges are 95% CI unless otherwise stated

Abbreviations:

AE: adverse event; EORTC: European Organization for Research and Treatment of Cancer; HR: hazards ratio; ICB: immune checkpoint blockade; NA: not applicable; ORR: objective response rate; OS: overall survival; PFS2: second progression-free survival; PLD: pegylated liposomal doxorubicin; SOC: standard of care; TSST: time to second subsequent therapy; mo: months; q2w: once every 2 weeks; q3w: once every 3 weeks